Previous Close | 17.98 |
Open | 17.78 |
Bid | 17.10 x 1000 |
Ask | 17.33 x 800 |
Day's Range | 17.23 - 18.08 |
52 Week Range | 6.51 - 22.76 |
Volume | |
Avg. Volume | 706,601 |
Market Cap | 1.291B |
Beta (5Y Monthly) | 0.70 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.90 |
Earnings Date | Feb 06, 2023 - Feb 10, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 21.78 |
WALTHAM, Mass., January 24, 2023--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the closing of its underwritten public offering of 7,986,111 shares of its common stock. The shares of common stock sold include 1,041,666 shares pursuant to the option granted by Deciphera to the underwriters, which option was exercised in full. The
WALTHAM, Mass., January 24, 2023--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the presentation of additional data from the planned exploratory analysis from the INTRIGUE Phase 3 clinical study of QINLOCK® using circulating tumor DNA (ctDNA) from patients with gastrointestinal stromal tumor (GIST) previously treated with imatin
WALTHAM, Mass., January 20, 2023--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the pricing of an underwritten public offering of 6,944,445 shares of its common stock at a public offering price of $18.00 per share. The aggregate gross proceeds to Deciphera from this offering are expected to be approximately $125 million, before